http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
UNITY Biotechnology (UBX) Reports Complete Patient Enrollment in Phase 1b Study of UBX0101
-
UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101
-
UNITY Biotechnology Announces Start of New CEO and New Employment Inducement Grants
-
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results
-
UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2019 Financial Results
-
UNITY Biotechnology Appoints Anirvan Ghosh, Ph.D. as Chief Executive Officer
-
UNITY Biotechnology (UBX) Provides Pipeline and Business Updates
-
UNITY Biotechnology Provides Pipeline and Business Updates
-
UNITY Biotechnology, Inc. to Participate in the Cowen and Company 40th Annual Health Care Conference
-
UNITY Biotechnology, Inc. Reports Third Quarter 2019 Financial Results and Business Updates
-
UNITY Biotechnology (UBX) Reports First Patient Dosed in Ph. 2 Study of UBX0101 in Osteoarthritis of the Knee
-
UNITY Biotechnology, Inc. Announces First Patient Dosed in Phase 2 Study of UBX0101 in Osteoarthritis of the Knee
-
UNITY Biotechnology, Inc. Announces Upcoming Scientific Presentations at ACR 2019 Annual Meeting
-
Unity Biotechnology, Inc. to Announce Third Quarter 2019 Financial Results
-
UNITY Biotechnology, Inc. to Participate in the 2019 Cantor Global Healthcare Conference
-
UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences
-
UNITY Biotechnology, Inc. Reports Second Quarter 2019 Financial Results and Program Updates
-
UNITY Biotechnology (UBX) Highlights Plan for Phase 2 Clinical Study of UBX0101 in Osteoarthritis of the Knee
-
UNITY Biotechnology, Inc. Announces Plan for Phase 2 Clinical Study of UBX0101 in Osteoarthritis of the Knee
-
UNITY Biotechnology, Inc. To Announce Second Quarter 2019 Financial Results
-
UNITY Biotechnology (UBX) Reports Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee
-
UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee
-
UNITY Biotechnology, Inc. and UCSF Enter Exclusive License Agreement on alpha-Klotho Protein for the Treatment of Age-Related Cognitive Decline
-
UNITY Biotechnology, Inc. to Present at Upcoming Investor Conferences
-
UNITY Biotechnology, Inc. Reports First Quarter 2019 Financial Results
-
UNITY Biotechnology, Inc. to Announce First Quarter 2019 Financial Results
-
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Program Updates
-
UNITY Biotechnology, Inc. to Participate in the Cowen 39th Annual Health Care Conference
-
CORRECTING and REPLACING -- UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
-
UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
-
UNITY Biotechnology (UBX) Announces Expansion of Ongoing UBX0101 Phase 1 Study to Further Evaluate SASP Factors in Osteoarthritis of Knee
-
UNITY Biotechnology Expands Ongoing UBX0101 Phase 1 Study to Further Evaluate SASP Factors in Osteoarthritis of the Knee
-
UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye
-
UNITY Biotechnology (UBX) Names Margo Roberts PhD to Board
-
UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors
-
UNITY Biotechnology Announces Additional Cohort to Evaluate Higher Dose in Ongoing UBX0101 Phase 1 Study in Osteoarthritis of the Knee
-
UNITY Biotechnology, Inc. to Host Investor & Analyst Event on Cellular Senescence
-
UNITY Biotechnology, Inc. Reports Third Quarter 2018 Financial Results
-
UNITY Biotechnology, Inc. to Announce Third Quarter 2018 Financial Results
-
UNITY Biotechnology, Inc. to Participate in the Cantor Fitzgerald Annual Global Healthcare Conference
-
UNITY Biotechnology, Inc. to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference
-
UNITY Biotechnology, Inc. Reports Second Quarter 2018 Financial Results
-
UNITY Biotechnology, Inc. to Announce Second Quarter 2018 Financial Results
-
UNITY Biotechnology Inc. (UBX) Reports First Patient Treated in UBX0101 Phase 1 Trial for Osteoarthritis of the Knee
-
UNITY Biotechnology, Inc. Announces First Patient Treated in UBX0101 Phase 1 Trial for Osteoarthritis of the Knee
-
UNITY Biotechnology, Inc. Added to Russell 3000®, 2000® and MicroCap® Indexes
-
UNITY Biotechnology, Inc. Reports First Quarter 2018 Financial Results
-
UNITY Biotechnology, Inc. to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
-
UNITY Biotechnology, Inc. to Announce First Quarter 2018 Financial Results

